Connect Biopharma (ADR) (CNTB)
Develops rademikibart for asthma and COPD outside Greater China.
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – Cash runway expected for a period of at least one year from the date of this release – SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three and six months ended June 30, 2026, and provided a business update. “During the second quarter, we achieved important milestones with the completion of enrollment in both our Phase 2 Seabreeze STAT asthma and chronic obstructive pulmonary disease (COPD) studies.
Brokerages Set Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Price Target at $7.29
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12-month
Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent
CNTB is developing rademikibart, a drug with a similar mechanism of action to SNY/REGN's blockbuster Dupixent. The company is approaching a readout from two trials, Seabreeze STAT Asthma and Seabreeze STAT COPD, which have the potential to show a benefit of rademikibart for acute exacerbations. CNTB raised net proceeds of $18.6M in Q1'26 with a private placement, with cash of $46M at the end of that quarter.
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway into 2H 2027 – SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study evaluating the safety and efficacy of rademikibart, the Company's next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, as an adjunct to standard of care for acute exacerbations in participants with asthma and type 2 inflammation. “Completion of enrollment in our Seabreeze STAT Asthma study marks another significant step in our mission to deliver the first biologic to treat patients suffering from an acute exacerbation of asthma,” said Barry Quart, Pharm.D.
Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026
Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits mid-2026 data from its SEABREEZE study.
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at 9:30 a.m. ET.
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis –
Connect Biopharma: New Market Opportunity In The Emergency Setting
Connect Biopharma Holdings is rated a risky Buy, with high upside potential hinging on mid-2026 Phase 2 trial results for rademikibart. Rademikibart has shown superior efficacy and safety to Dupixent in China Phase 3 trials, with commercialization led by Simcere and low-double-digit royalties to CNTB. CNTB is targeting the emergency asthma and COPD settings in the US, a market with no approved biologics, and expects pivotal Phase 2 data in mid-2026.
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the independent Data Monitoring Committee (DMC) overseeing its Phase 2 Seabreeze STAT asthma and COPD trials evaluating rademikibart, the Company's next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, has completed its review of the pre-specified interim analysis of efficacy with no recommendation for change in the sample size. “Based on the DMC's review of interim efficacy results from our ongoing Seabreeze STAT acute asthma and COPD studies, enrollment will continue as planned with no change in sample size,” said Barry Quart, Pharm.D.
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session at AAD – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies mid-2026 – – Entered into a securities purchase agreement for $20.2 million equity financing extending our cash runway into second half of 2027 – SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three and twelve months ended December 31, 2025, and provided a business update. “2025 was an eventful year for our lead drug candidate, rademikibart, with the initiation of our Phase 2 Seabreeze STAT studies in acute asthma and chronic obstructive pulmonary disease (COPD),” said Barry Quart, Pharm.D.
Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript
Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript
Connect Biopharma Announces $20.2 Million Private Placement Financing
Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 6,130,000 shares of its ordinary shares in a private placement at a price of $3.25 per share with respect to any purchaser that is not owned or controlled by an individual who is an officer, director, employee or consultant of the Company. Connect anticipates the gross proceeds from the private placement will be approximately $20.2 million, before deducting placement agent fees and other offering expenses.
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near ‑ maximal responses achieved in ~90% of patients –
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV 1 with many patients experiencing improvements in airway function of ≥200 mL as early as 15 minutes post-dosing –
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the results of a Phase 3 study of rademikibart in moderate-to-severe atopic dermatitis (AD) conducted by the Company's partner in China, Simcere Pharmaceutical Co., Ltd. (Simcere), will be presented in the Late-Breaking Research session at the 2026 AAD Annual Meeting, which takes place March 27-31, 2026, in Denver, Colorado.
Connect Biopharma Touts Rademikibart as Fast-Acting Option for Acute Asthma, COPD Flare-Ups at Conference
Connect Biopharma (NASDAQ: CNTB) CEO Barry Quart told investors at Oppenheimer's 36th Annual Healthcare Life Science Conference that the company is advancing its lead asset, rademikibart, into what it described as a novel treatment approach for acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). Quart said the company believes rademikibart's binding characteristics and rapid
BML Capital Management LLC Sells 554,058 Shares of Connect Biopharma Holdings Limited Sponsored ADR $CNTB
BML Capital Management LLC cut its stake in Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB) by 30.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,267,500 shares of the company's stock after selling 554,058 shares during the quarter. Connect Biopharma
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Rating of “Moderate Buy” by Analysts
Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Receives Average Rating of “Moderate Buy” from Brokerages
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has assigned a strong buy